Drug Approval | August 11, 2025
Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
His career spans notable tenures at Syngene International Limited, Cipla, Nestlé, and Bharat Petroleum Corporation Limited
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Subscribe To Our Newsletter & Stay Updated
